Removing Traditional
Limitations on
Administering Therapies

Halozyme’s ENHANZE® drug delivery technology is based on our patented recombinant human hyaluronidase enzyme , rHuPH20 to enable and optimize subcutaneous drug delivery for appropriate co-administered therapies.

With the technology, some biologics and compounds that are administered intravenously may instead be delivered subcutaneously, or under the skin, potentially providing a better experience for patients, and reactions increasing health system efficiencies by reducing administration and nursing time, increasing patient throughput, reducing product waste, and decreasing overall healthcare expenses.

For more information, download Delivering a Volume of Benefits.

Halozyme has collaboration agreements for the ENHANZE technology with Roche, Pfizer, Janssen, Baxalta, AbbVie, Eli Lilly, Bristol-Myers Squibb and Alexion.


For more information on partnering with Halozyme, please contact a member of the Business Development Team.


You are now leaving Halozyme is not responsible for or endorses the content of the linked site.